Inozyme Story

Our current technical analysis of Inozyme Pharma (NASDAQ:INZY)
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Inozyme Pharma. In general, we focus on analyzing Inozyme Pharma stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Inozyme Pharma's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Inozyme Pharma's intrinsic value. In addition to deriving basic predictive indicators for Inozyme Pharma, we also check how macroeconomic factors affect Inozyme Pharma price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research. Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Inozyme Pharma's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Inozyme Pharma in the context of predictive analytics.

Hype Prediction Details

Intrinsic Valuation Details

Naive Forecast Details

4 Analysts Consensus Details

Please note, it is not enough to conduct a financial or market analysis of a single entity such as Inozyme Pharma. Your research has to be compared to or analyzed against Inozyme Pharma's peers to derive any actionable benefits. When done correctly, Inozyme Pharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Inozyme Pharma.

How does Inozyme Stands against Peers?

Analyzing Inozyme Pharma competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Inozyme Pharma across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be. Check out Inozyme Pharma Competition Details

How Inozyme utilizes its cash?

To perform a cash flow analysis of Inozyme Pharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Inozyme Pharma is receiving and how much cash it distributes out in a given period. The Inozyme Pharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Inozyme Pharma Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Inozyme Pharma reported Net Cash Flow from Operations of (16.93 Million) in 2020

Acquisition by Basso Stephen of 41794 shares of Inozyme Pharma subject to Rule 16b-3

Legal trades by Inozyme Pharma insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

Inozyme insider trading alert for grant of stock option (right to buy) by Basso Stephen, SVP Finance (PFO), on 14th of January 2021. This event was filed by Inozyme Pharma Inc with SEC on 2021-01-14. Statement of changes in beneficial ownership - SEC Form 4 [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Details

About Contributor